| Literature DB >> 31965215 |
Jonathan S Palmer1, Luke D Jones2, A Paul Monk3, Michael Nevitt4, John Lynch4, David J Beard5, M K Javaid5, Andrew J Price6.
Abstract
PURPOSE: Lower limb malalignment is a strong predictor of progression in knee osteoarthritis. The purpose of this study is to identify the individual alignment variables that predict progression in early to moderate osteoarthritis of the knee.Entities:
Keywords: Coronal; Knee; MPTA; Mechanical alignment; Osteoarthritis; Proximal tibial angle
Mesh:
Year: 2020 PMID: 31965215 PMCID: PMC7511471 DOI: 10.1007/s00167-019-05840-5
Source DB: PubMed Journal: Knee Surg Sports Traumatol Arthrosc ISSN: 0942-2056 Impact factor: 4.342
Fig. 1Formation of the study cohort. Flowchart illustrates the formation of the study cohort. *Timepoint at which FLRs were taken; 12 months (n = 965), 24 months (n = 230), 36 months (n = 112), 48 months (n = 20)
Characteristics of the study cohort
| Characteristic | Study cohort ( |
|---|---|
| Age (mean; SD) | 60.7 (± 8.9) |
| Sex (% female) | 57% |
| BMI (kg/m2; mean) | 29.9 |
| Race (% Caucasian) | 69.8% |
| Co-morbidities (% none) | 70.5% |
| Smoker (%) | 7.2% |
| KL grade (%) | 1 = 17% 2 = 50% 3 = 33% |
Fig. 2Alignment variables were obtained using Medicaid® Classic (Hectec GMBH) for all individuals within the cohort. Mechanical alignment measurements included weight-bearing axis (WBA), mechanical lateral proximal femoral angle (mLPFA), mechanical lateral distal femoral angle (mLDFA), medial proximal tibial angle (MPTA), mechanical lateral distal tibial angle (mLDTA) and joint line convergence angle (JLCA). The light blue line indicates the weight-bearing axis expressed as a percentage of the medial–lateral tibial plateau (35.3% in this plan). NB: the outline of the femur and tibia has been highlighted in white to aid interpretation of this figure
The difference in alignment variables by gender is summarised
| Males ( | Females ( | |||
|---|---|---|---|---|
| Mean | SD | Mean | SD | |
| mLPFA | 91.8° | 5.4 | 92.0° | 5.8 |
| mLDFA* | 87.5° | 2.0 | 87.3° | 2.4 |
| MPTA* | 86.6° | 2.3 | 87.9° | 2.4 |
| mLDTA* | 86.2° | 4.0 | 87.3° | 3.5 |
| JLCA_med | 1.3° | 1.6 | 1.1° | 1.9 |
*Indicates a significant difference by gender (p < 0.05)
Fig. 3Kernel density plot graphs illustrating the differences in alignment variables observed by baseline KL grade. *p ≤ 0.05
The influence of alignment variables on overall alignment is summarised
| Alignment | Predictor | Odds ratio | 95% CI | Standardised coefficient | |
|---|---|---|---|---|---|
| Varus | mLPFA | 1.03 | 0.99–1.08 | 0.15 | 0.02 |
| mLDFA* | 3.63 | 2.57–5.12 | < 0.001 | 0.58 | |
| MPTA* | 0.23 | 0.16–0.34 | < 0.001 | − 0.60 | |
| mLDTA* | 1.11 | 1.04–1.19 | 0.003 | 0.03 | |
| Valgus | mLPFA | 0.97 | 0.93–1.02 | 0.20 | − 0.005 |
| mLDFA* | 0.27 | 0.19–0.39 | < 0.001 | − 0.58 | |
| MPTA* | 4.44 | 2.91–6.77 | < 0.001 | 0.61 | |
| mLDTA* | 0.90 | 0.84–0.97 | 0.005 | − 0.03 |
*p ≤ 0.05
Multivariate regression analysis to determine the influence of all baseline variables on symptom worsening (WOMAC > 9 points) and structural progression (JSN > 0.7 mm) over 24 months
| Variable of interest | Symptom worsening (WOMAC > 9 points) | Structural progression (JSN > 0.7 mm) | ||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | Odds ratio | 95% CI | |||
| Baseline WOMAC* | 0.97 | 0.95–0.98 | < 0.001 | 1.01 | 1.00–1.02 | 0.16 |
| Baseline JSN | 0.95 | 0.80–1.13 | 0.53 | 1.06 | 0.89–1.27 | 0.50 |
| Age | 0.99 | 0.96–1.02 | 0.41 | 1.01 | 0.98–1.04 | 0.56 |
| Gender | 1.46 | 0.90–2.37 | 0.13 | 1.18 | 0.70–1.98 | 0.53 |
| BMI* | 1.06 | 1.01–1.11 | 0.01 | 1.02 | 0.97–1.07 | 0.39 |
| Co-morbidities | 1.10 | 0.90–1.40 | 0.45 | 0.89 | 0.66–1.16 | 0.36 |
| Race | 0.76 | 0.47–1.24 | 0.27 | 1.15 | 0.67–1.96 | 0.62 |
| Employment | 0.63 | 0.38–1.05 | 0.07 | 1.22 | 0.70–2.12 | 0.49 |
| Smoker | 1.25 | 0.82–1.92 | 0.30 | 1.30 | 0.82–2.06 | 0.27 |
| Previous knee surgery | 1.19 | 0.70–2.00 | 0.52 | 0.97 | 0.56–1.69 | 0.91 |
| mLPFA | 1.03 | 0.99–1.06 | 0.18 | 1.02 | 0.98–1.06 | 0.39 |
| mLDFA | 0.92 | 0.84–1.01 | 0.09 | 1.05 | 0.95–1.16 | 0.35 |
| MPTA** | 1.05 | 0.96–1.15 | 0.31 | 0.79 | 0.71–0.88 | < 0.001 |
| mLDTA | 1.02 | 0.96–1.08 | 0.59 | 1.02 | 0.96–1.08 | 0.50 |
*Indicates significant predictor of symptom worsening at 24 months (p < 0.05)
**Indicates significant predictor of structural progression at 24 months (p < 0.05)